Unlike many other cancers, most pancreatic tumors are rock hard.
“That’s one reason why pancreatic cancer is one of the most lethal types of cancer,” says Kenneth Olive, PhD, associate professor of medicine and pathology & cell biology at Columbia University Vagelos College of Physicians and Surgeons and a pancreatic cancer researcher at the Herbert Irving Comprehensive Cancer Center.
“Pancreatic tumors recruit a thick layer of connective tissue called stroma that hardens the tumor and acts like a shield,” says Olive, whose previous research first uncovered how the stroma makes it difficult for chemotherapy drugs to reach malignant cells. “As a result, most chemotherapy drugs can’t build up to the levels needed to be effective.”
To Olive, that suggests, paradoxically, a longer-lived—but less toxic—drug may work better.
“For a pancreatic cancer drug to be effective, it needs to stick around long enough to seep past the stroma and accumulate in the tumor. But if it is going to persist for a long time in the blood, it can’t be as toxic to the rest of the body,” he says.
Pancreatic Ductal Adenocarcinoma
Despite some recent improvements in pancreatic cancer treatment, the five-year survival rate for individuals with this disease is only around 9%.
Testing a New Drug Combination
Olive’s latest research, which was led by Jaime Eberle-Singh, PhD, while she was a graduate student at Columbia, may have identified a good candidate. The drug, an experimental compound called PTC596 that had shown antitumor activity in mouse and human pancreatic cancer cells, seemed to have the right qualities: PTC596 has a durable half-life (most cancer drugs have a half-life of a few minutes to hours) and can evade a pump that many cancer cells use to expel drugs. “This means that any amount of drug that makes it past the barrier can target the malignant cells,” says Olive.
Based on those studies, Olive, Eberle-Singh, and their collaborators tested PTC596 in combination with gemcitabine (a first-line drug for pancreatic cancer) in genetically engineered mice with an aggressive form of pancreatic cancer that is generally resistant to chemotherapy.
The mice that were treated with the two-drug combination lived three times longer than those treated with only a single standard agent. “This result was exciting because it’s exceedingly rare for any treatment to extend survival in this gold-standard mouse model,” Olive says.
They also tested PTC596 in combination with gemcitabine and another drug commonly used to treat pancreatic cancer, nab-paclitaxel, using human pancreatic tumors grown in mice. This combination further enhanced efficacy, making the tumors shrink outright.
“Based on the drug’s safety profile and our own findings, there’s a good rationale for testing PTC596 in combination with standard therapy in patients with pancreatic cancer,” says Olive.
Olive’s team also discovered that PTC596 blocks the formation of microtubules—a network of proteins involved in cell division and transport of nutrients within the cell. He demonstrated that PTC596 may act synergistically with nab-paclitaxel, another microtubule-binding agent.
“Combining different microtubule inhibitors has the potential to play an important role in the future of oncology, as there are many agents that each impact microtubules in different ways that could produce synergy,” Olive says.
The Latest on: Pancreatic cancer
via Google News
The Latest on: Pancreatic cancer
- Cancer acts like bacteria to resist drugson June 4, 2020 at 11:45 am
Cancer cells can turn on error-prone DNA copy pathways to adapt to cancer treatment in much the same way as bacteria develop antibiotic resistance, new research has revealed. The process is known as ...
- Revealed: How cancer develops resistance to treatmenton June 4, 2020 at 11:01 am
Cancer cells can turn on error-prone DNA copy pathways to adapt to cancer treatment, a breakthrough study published in the journal Science has revealed. Bacteria use the same process, termed ...
- This Is Why Pancreatic Cancer Is So Hard to Treaton June 4, 2020 at 8:00 am
Pancreatic cancer is difficult to treat largely because the early signs are vague, the cancer is highly aggressive, and no screening test exists yet. But the future is starting to look hopeful. The ...
- Colorado celebrates 10 years of PurpleStride, the walk to end pancreatic canceron June 2, 2020 at 10:56 am
Thousands will virtually walk to end pancreatic cancer, the world’s toughest cancer, on Saturday, June 28 at PurpleStride Colorado, hosted by the Pancreatic Cancer Action Network (PanCAN) Colorado ...
- Identifying Patients With Pancreatic Cancer Likely to Respondon June 2, 2020 at 6:37 am
Identification of DNA repair mutations singles out patients with advanced pancreatic cancer who respond best to first-line platinum chemotherapy.
- The lncRNA RUNX1-IT1 regulates C-FOS transcription by interacting with RUNX1 in the process of pancreatic cancer proliferation, migration and invasionon June 2, 2020 at 1:32 am
Numerous long noncoding RNAs (lncRNAs) are aberrantly expressed in pancreatic cancer (PC); however, their functions and mechanisms in cancer progression are largely unknown. In this study, we ...
- The genomic landscape of recurrent pancreatic cancer is modified by treatmenton June 1, 2020 at 4:36 am
Most patients who undergo curative intent surgery for pancreatic cancer will still die of recurrent disease. A new study shows that pancreatic tumours that pass through the genetic bottlenecks of ...
- Research provides guidance for treating pancreatic cancer patients during COVID-19 pandemicon May 27, 2020 at 7:09 pm
The novel coronavirus (COVID-19) pandemic not only affects patients who have the virus, but strikes the entire healthcare system including the care for patients with cancer.
- Despite COVID-19, pivotal pancreatic cancer study in Israel hits benchmarkon May 24, 2020 at 11:36 pm
Overall survival rate increased from 11.1 months to 19.9 in some trials. The 613 in CPI-613 stands for the 613 commandments of the Torah.
- Long-term pancreatic cancer survivor shares his journey of hopeon May 24, 2020 at 5:06 pm
I was diagnosed with pancreatic cancer, one of the toughest malignancies to treat. I am fortunate to be a long-term survivor of such a difficult-to-beat cancer, but I am also proof that where there is ...
via Bing News